RISS 학술연구정보서비스

검색

인기 검색어

    다국어 입력

    http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

    변환된 중국어를 복사하여 사용하시면 됩니다.

    예시)
    • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
    • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
    닫기
    KCI등재 SCIE SCOPUS

    JAK2 V617F and Exon 12 Genetic Variations in Korean Patients with BCR/ABL1-negative Myeloproliferative Neoplasms

    한글로보기

    https://www.riss.kr/link?id=A101631469

    • 0

      상세조회
    • 0

      다운로드
    서지정보 열기
    • 내보내기
    • 내책장담기
    • 공유하기
      • URL 복사
    • 오류접수
    인용문이 복사되었습니다.

    부가정보

    다국어 초록 (Multilingual Abstract) kakao i 다국어 번역

    Background : JAK2 genetic variations have been described in a high proportion of patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). This study was designed to analyze the frequencies of JAK2 V617F and exon 12 variations, and their correlations with clinical characteristics of Korean patients with BCR/ABL1-negative MPN.
    Methods : We examined a total of 154 patients with BCR/ABL1-negative MPN that included 24, 26, 89, and 15 patients with polycythemia vera (PV), primary myelofibrosis (PMF), essential thrombocythemia (ET), and unclassified myeloproliferative neoplasms (MPNU), respectively. We performed allele-specific PCR to detect V617F in all BCR/ABL1-negative patients, and performed direct sequencing to detect exon 12 variations in 47 V617F-negative MPN patients. JAK2 c.1641+179_183del5 variation was detected by restriction fragment length polymorphism assay in 176 healthy subjects.
    Results : JAK2 V617F was detected in 91 patients (59.1%): PV (91.6%), PMF (46.2%), ET (52.8%), and MPNU (66.7%). In V617F-negative MPN patients, no mutations were found in exon 12. The c.1641+179_183del5 was detected in 68.1% of V617F-negative MPN patients and 45.4% of healthy subjects (P=0.008). JAK2 V617F was closely correlated with age and leukocytosis in BCR/ABL1-negative MPN patients (P<0.05). However, c.1641+179_183del5 was not related to age, sex, or complete blood cell count parameters in V617F-negative MPN patients and healthy subjects. The c.1641+179_183del5 was associated with an increased odds ratio for MPN (odds ratio, 2.6;95% confidences interval, 1.3-5.1; P=0.007).
    Conclusions : Frequencies of V617F are similar to reported results. JAK2 exon 12 mutations may be rare and c.1641+179_183del5 may influence the occurrence of MPN in Korean patients with V6 17F-negative MPN. (Korean J Lab Med 2010;30:567-74)
    번역하기

    Background : JAK2 genetic variations have been described in a high proportion of patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). This study was designed to analyze the frequencies of JAK2 V617F and exon 12 variations, and their cor...

    Background : JAK2 genetic variations have been described in a high proportion of patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). This study was designed to analyze the frequencies of JAK2 V617F and exon 12 variations, and their correlations with clinical characteristics of Korean patients with BCR/ABL1-negative MPN.
    Methods : We examined a total of 154 patients with BCR/ABL1-negative MPN that included 24, 26, 89, and 15 patients with polycythemia vera (PV), primary myelofibrosis (PMF), essential thrombocythemia (ET), and unclassified myeloproliferative neoplasms (MPNU), respectively. We performed allele-specific PCR to detect V617F in all BCR/ABL1-negative patients, and performed direct sequencing to detect exon 12 variations in 47 V617F-negative MPN patients. JAK2 c.1641+179_183del5 variation was detected by restriction fragment length polymorphism assay in 176 healthy subjects.
    Results : JAK2 V617F was detected in 91 patients (59.1%): PV (91.6%), PMF (46.2%), ET (52.8%), and MPNU (66.7%). In V617F-negative MPN patients, no mutations were found in exon 12. The c.1641+179_183del5 was detected in 68.1% of V617F-negative MPN patients and 45.4% of healthy subjects (P=0.008). JAK2 V617F was closely correlated with age and leukocytosis in BCR/ABL1-negative MPN patients (P<0.05). However, c.1641+179_183del5 was not related to age, sex, or complete blood cell count parameters in V617F-negative MPN patients and healthy subjects. The c.1641+179_183del5 was associated with an increased odds ratio for MPN (odds ratio, 2.6;95% confidences interval, 1.3-5.1; P=0.007).
    Conclusions : Frequencies of V617F are similar to reported results. JAK2 exon 12 mutations may be rare and c.1641+179_183del5 may influence the occurrence of MPN in Korean patients with V6 17F-negative MPN. (Korean J Lab Med 2010;30:567-74)

    더보기

    참고문헌 (Reference)

    1 안정열1, "한국인 본태성혈소판혈증 환자에서 JAK2V617F 유전자 변이" 대한진단검사의학회 27 (27): 77-82, 2007

    2 Jones AV, "Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders" 106 : 2162-2168, 2005

    3 Butcher CM, "Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients" 22 : 870-873, 2008

    4 Percy MJ, "The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels" 92 : 1607-1614, 2007

    5 Vardiman JW, "The World Health Organization (WHO) classification of the myeloid neoplasms" 100 : 2292-2302, 2002

    6 Jones AV, "The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms" 115 : 4517-4523, 2010

    7 Pardanani A, "The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients" 24 : 110-114, 2010

    8 Barosi G, "The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia" 104 : 730-737, 1999

    9 Pietra D, "Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders" 111 : 1686-1689, 2008

    10 Saharinen P, "Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain" 20 : 3387-3395, 2000

    1 안정열1, "한국인 본태성혈소판혈증 환자에서 JAK2V617F 유전자 변이" 대한진단검사의학회 27 (27): 77-82, 2007

    2 Jones AV, "Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders" 106 : 2162-2168, 2005

    3 Butcher CM, "Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients" 22 : 870-873, 2008

    4 Percy MJ, "The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels" 92 : 1607-1614, 2007

    5 Vardiman JW, "The World Health Organization (WHO) classification of the myeloid neoplasms" 100 : 2292-2302, 2002

    6 Jones AV, "The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms" 115 : 4517-4523, 2010

    7 Pardanani A, "The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients" 24 : 110-114, 2010

    8 Barosi G, "The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia" 104 : 730-737, 1999

    9 Pietra D, "Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders" 111 : 1686-1689, 2008

    10 Saharinen P, "Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain" 20 : 3387-3395, 2000

    11 Watanabe S, "Roles of the JAK-STAT system in signal transduction via cytokine receptors" 6 : 587-596, 1996

    12 Levine RL, "Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders" 7 : 673-683, 2007

    13 Michiels JJ, "Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group" 23 : 339-347, 1997

    14 Kurzrock R, "Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics" 138 : 819-830, 2003

    15 Tefferi A, "Oncogenes in myeloproliferative disorders" 6 : 550-566, 2007

    16 "NCBI Single Nucleotide Polymorphism"

    17 Delhommeau F, "Molecular aspects of myeloproliferative neoplasms" 91 : 165-173, 2010

    18 Scott LM, "JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis" 245 : 459-468, 2007

    19 Quentmeier H, "JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders" 20 : 471-476, 2006

    20 Barosi G, "JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis" 110 : 4030-4036, 2007

    21 Bousquet M, "Frequent detection of the JAK2 V617F mutation in bone ma-rrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations" 37 : 1458-1464, 2006

    22 Aplenc R, "Differential bone marrow aspirate DNA yields from commercial extraction kits" 16 : 1865-1866, 2002

    23 Soo-Mee Bang, "Diagnostic Usefulness of the Janus Kinase 2 Mutation in non­BCR/ABL Myeloproliferative Disorders" 대한내과학회 21 (21): 219-224, 2006

    24 Horn T, "Detection of the activating JAK2 V617F mutation in paraffinembedded trephine bone marrow biopsies of patients with chronic myeoproliferative diseases" 8 : 299-304, 2006

    25 Lay M, "Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis" 8 : 330-334, 2006

    26 Schnittger S, "Detection of JAK2 exon 12 mutations in 15 patients with JAK2 V617F negative polycythemia vera" 94 : 414-418, 2009

    27 Speletas M, "Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders" 31 : 1053-1062, 2007

    28 Saltzman A, "Cloning and characterization of human Jak-2 kinase: high mRNA expression in immune cells and muscle tissue" 246 : 627-633, 1998

    29 Tefferi A, "Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms" 22 : 14-22, 2008

    30 Levine RL, "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis" 7 : 387-397, 2005

    31 Baxter EJ, "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders" 365 : 1054-1061, 2005

    32 Tan AY, "A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation" 127 : 977-981, 2007

    33 Kralovics R, "A gain-of-function mutation of JAK2 in myeloproliferative disorders" 352 : 1779-1790, 2005

    더보기

    분석정보

    View

    상세정보조회

    0

    Usage

    원문다운로드

    0

    대출신청

    0

    복사신청

    0

    EDDS신청

    0

    동일 주제 내 활용도 TOP

    더보기

    주제

    연도별 연구동향

    연도별 활용동향

    연관논문

    연구자 네트워크맵

    공동연구자 (7)

    유사연구자 (20) 활용도상위20명

    인용정보 인용지수 설명보기

    학술지 이력

    학술지 이력
    연월일 이력구분 이력상세 등재구분
    2023 평가 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
    2020-01-01 등재 등재학술지 유지 (해외등재 학술지 평가) KCI등재
    2012-05-21 학술지명변경 한글명 : The Korean Journal of Laboratory Medicine -> Annals of Laboratory Medicine
    외국어명 : The Korean Journal of Laboratory Medicine -> Annals of Laboratory Medicine
    KCI등재
    2011-01-01 등재 학술지 분리 (기타) KCI등재
    2010-06-29 학술지명변경 한글명 : 대한진단검사의학회지 -> The Korean Journal of Laboratory Medicine KCI등재
    2009-01-01 등재 등재학술지 유지 (등재유지) KCI등재
    2007-01-01 등재 등재학술지 유지 (등재유지) KCI등재
    2005-01-01 등재 등재학술지 유지 (등재유지) KCI등재
    2002-01-01 등재 등재학술지 선정 (등재후보2차) KCI등재
    1999-07-01 등재 등재후보학술지 선정 (신규평가) KCI등재후보
    더보기

    학술지 인용정보

    학술지 인용정보
    기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
    2016 1.51 0.18 1.15
    KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
    0.91 0.81 0.458 0.08
    더보기
    해외이동버튼